An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

ABSTRACT: The third-generation aromatase inhibitors (AIS) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor-positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have demonstrated improved disease-free survival with AI treatment. Trials have included direct 5-year comparisons between tamoxifen and an AI, switching to an AI within 5 years after initial tamoxifen treatment, or extending treatment with an AI after 5 years of completed tamoxifen treatment. Some of these trials have been completed; others are ongoing; and head-to-head trial comparisons of individual AIS are also in progress. The present article summarizes the data obtained from various clinical tri

SUBMITTER: Verma S 

PROVIDER: S-EPMC2722048 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature